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Abstract
Purpose—Perceived discrimination has been associated with lower adherence to cancer 
screening guidelines. We examined whether perceived discrimination was associated with 
adherence to breast, cervical, colorectal, and prostate cancer screening guidelines in US Hispanic/
Latino adults.
Methods—Data were obtained from the Hispanic Community Health Study/Study of Latinos 
Sociocultural Ancillary Study, including 5,313 Hispanic adults ages 18–74 from Bronx NY, 
Chicago IL, Miami FL, and San Diego CA who were within appropriate age ranges for specific 
screening tests were included in the analysis. Cancer screening behaviors were assessed via self-
report. Perceived discrimination was measured using the Perceived Ethnic Discrimination 
Questionnaire. Confounder-adjusted multivariable polytomous logistic regression models assessed 
the association between perceived discrimination and adherence to cancer screening guidelines.
Results—Among women eligible for screening, 72.1% were adherent to cervical cancer 
screening guidelines and 71.3% were adherent to breast cancer screening guidelines. In 
participants aged 50–74, 24.6% of women and 27.0% of men were adherent to fecal occult blood 
test guidelines; 43.5% of women and 34.8% of men were adherent to colonscopy/sigmoidoscopy 
guidelines; 41.0% of men were adherent to prostate specific antigen screening guidelines. Health 
insurance coverage, rather than perceived ethnic discrimination, was the variable most associated 
with receiving breast, cervical, colorectal, or prostate cancer screening.
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Conclusions—The influence of discrimination as a barrier to cancer screening may be modest 
among Hispanics/Latinos in urban US regions. Having health insurance facilitates cancer 
screening in this population. Efforts to increase cancer screening in Hispanics/Latinos should 
focus on increasing access to these services, especially among the uninsured.
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INTRODUCTION
Cancer has recently surpassed heart disease as the leading cause of death among Hispanics/
Latinos in the US 1. Although the incidence of many major cancers including breast, 
cervical, colorectal, and prostate cancer is lower in Hispanics/Latinos than in non-Hispanic 
whites, Hispanics/Latinos are more likely than non-Hispanic whites to be diagnosed at later 
stages of cancer when the disease is more difficult to treat 1. Lower rates of cancer screening 
in Hispanics/Latinos may contribute to their excess of late-stage cancer diagnoses 2. 
Hispanics/Latinos are less likely than non-Hispanic whites to receive screening for major 
cancers 2,3. Previous research has identified multiple individual and system level 
determinants of cancer screening in Hispanics/Latinos including education, acculturation, 
annual household income, health insurance coverage, health care access, physician supply, 
knowledge about cancer, and mistrust of the medical system 3–10. Recent evidence suggests 
that perceived discrimination is a barrier to preventive health behaviors, including cancer 
screening 11–14.
The Institute of Medicine identified racial and ethnic discrimination as one of the underlying 
contributors to health disparities 15. Perceived discrimination may be conceptualized as a 
stressor that has broad consequences for health 16. Discrimination may trigger a stress 
response and decrease an individual’s self-control resources, which may lead to 
nonparticipation in healthful behaviors, such as following cancer screening guidelines 16. A 
meta-analysis of studies concluded that individuals who perceived that they had experienced 
discrimination were less likely to engage in favorable health behaviors than those who did 
not report perceiving discrimination 16. Perceived discrimination has been associated with 
lower likelihood of receiving Pap smears in African American women 12. Perceived 
discrimination in the medical setting has been associated with failure to meet the 
recommendations in clinical guidelines for prostate, colorectal, and breast cancer 
screening 11,13,14.
While many studies have examined the association between perceived discrimination and 
cancer screening in African Americans, few studies have investigated this association among 
Hispanics/Latinos. The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) 
obtained information on perceptions of discrimination and cancer screening behaviors across 
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categories of Hispanic/Latino adults defined by national background. Unlike some prior 
studies, HCHS/SOL data captured detailed information on the timing of cancer screening 
tests, making it possible to examine recency as well as lifetime receipt of screening tests. We 
analyzed data from the HCHS/SOL Sociocultural Ancillary Study (SCAS) to determine if 
perceived discrimination is associated with adherence to cancer screening based on 
contemporary screening guidelines at the time of the baseline examination. We compare 
three different groups: those who have been screened and are adherent to the guidelines, 
those who have been screened but are not adherent to the guidelines, and those who have 
never been screened. We hypothesized that adherence to screening guidelines would be 
lower among those who perceive discrimination. Understanding the effect of perceived 
discrimination on adherence to cancer screening across the various subgroups of Hispanics 
will serve to inform the design of culturally tailored, targeted interventions that increase 
cancer screening adherence in Hispanics.
MATERIALS AND METHODS
Participants
The HCHS/SOL is a multi-centered observational study of 16,415 Hispanic/Latino men and 
women aged 18–74 years of age. The details of the study have been described 
elsewhere 17,18. Briefly, between 2008 and 2011, participants were recruited from four 
regions in the US: Bronx NY, Chicago IL, Miami FL, and San Diego CA using a two-stage 
probability sampling of households in selected census tracts. The cohort includes persons 
identifying as Dominican, Central American, Cuban, Mexican, Puerto Rican, South 
American or mixed/other. The SCAS is an ancillary study of the HCHS/SOL that enrolled a 
subset of 5,313 participants who, upon completing the main HCHS/SOL examination, were 
invited to return for additional psychosocial assessment that included measures of perceived 
discrimination and cancer screening within 6 months of their baseline examination. IRB 
approval was obtained at each field center and the coordinating center.
Cancer screening behaviors
The HCHS/SOL cancer questionnaire was used to measure cancer screening behaviors. This 
questionnaire inquired about the receipt of the following cancer screening tests: 
mammogram, Pap smear, fecal occult blood test (FOBT), colonscopy/sigmoidoscopy, and 
Prostate Specific Antigen (PSA).
To assess breast cancer screening women were asked, “A mammogram is an x-ray of the 
breast to look for breast cancer. Have you ever had a mammogram?” If yes, participants 
were asked, “When did you have your most recent mammogram to check for breast cancer?” 
Possible responses included: “a year ago or less,” “more than 1 but not more than 2 years 
ago,” “more than 2 but not more than 5 years ago” and “over 5 years ago.” Cervical cancer 
screening was assessed by asking women, “A pap smear is an exam to detect cancer of the 
neck of the uterus or cervix. Have you ever had a Pap smear?” If participants answered yes 
they were asked, “When did you have your most recent Pap smear?” Possible responses 
included: “a year ago or less,” “more than 1 but not more than 2 years ago,” “more than 2 
but not more than 5 years ago,” and “over 5 years ago.”
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To assess FOBT screening both men and women were asked, “Have you ever had a Fecal 
Occult Blood Test done with your doctor, in a clinic or using a home kit?” If they answered 
yes participants were then asked, “When was the last time you had a Fecal Occult Blood 
Test done with your doctor, in a clinic or using a home kit?”
To assess colonoscopy and/or sigmoidoscopy participants were asked: “Have you ever had 
either a colonoscopy or sigmoidoscopy?” Possible responses were “yes, a colonoscopy,” 
“yes, a sigmoidoscopy” and “no.” If participants answered yes to having either a 
colonoscopy or sigmoidoscopy, they were asked, “When did you have your most recent 
colonoscopy/sigmoidoscopy?” Responses included: “a year ago or less,” “more than 1 year 
ago but not more than 5 years ago,” “more than 5 but not more than 10 years ago,” and “over 
10 years ago.”
To assess PSA screening, men were asked, “Have you ever heard of a PSA or prostate-
specific antigen test?” Respondents that answered “yes” were asked, “Have you ever had a 
PSA test?” Possible responses included “No,” “Yes, I had a blood test but I don’t know if it 
checked PSA,” and “refused.” If men reported having a PSA they were asked, “When did 
you have your most recent PSA?” and possible responses included “A year ago or less,” 
“More than 1 but not more than 2 years ago,” “More than 2 but not more than 5 years ago,” 
and “over 5 years ago.”
Adherence to Cancer Screening guidelines
Adherence to breast, cervical, colorectal and prostate cancer screenings was defined as a 3-
level categorical variable (screened, adherent; screened, non-adherent; or not screened). 
Each type of cancer screening was assessed separately within recommended age group and 
sex. For the purpose of this study we defined adherence to the screening guidelines 
according to guidelines from United States Preventive Services Task Force (USPSTF) and 
the American Cancer Society (ACS) that were in effect during the study years (2008–2011). 
Adherent was defined as the participant was screened and the screening was within the 
recommended timeframe. Not adherent was defined as the participant was screened but the 
screening occurred outside of the recommended timeframe. For each screening test, 
participants who reported never receiving the test were categorized as “not screened.” A 
detailed description of adherence by cancer screening guidelines is provided in subsequent 
text and summarized in Online Resource 1.
Breast and cervical cancer screening—During 2008–2011, the ACS recommended 
that women 40 and older obtain a mammogram every year 19. In this same age group, the 
USPSTF recommended obtaining a mammogram every 1 to 2 years 20. The ACS and 
USPSTF both recommended an annual Papanicolaou (Pap) smear in women beginning three 
years after first vaginal intercourse but not later than 21 years of age 19,21. Since age of 
vaginal intercourse was not assessed, all women of reproductive age (age 18 years or older) 
were included for analysis regarding cervical cancer screening. Cervical cancer screening 
analyses were restricted to women age 18 years or older and breast cancer analyses were 
restricted to women age 40 years or older. Women participants were categorized as 
“screened, adherent” if they reported receipt of the screening test within 2 years, “screened, 
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non-adherent” if they reported receipt of screening test over 2 years prior, and “not 
screened” if never screened.
Colorectal cancer screening—For men and women age 50 and over, the ACS and 
USPSTF recommends an annual FOBT, a sigmoidoscopy every 5 years, or a colonoscopy 
every 10 years 19,22. Participants age 50 years and older reporting FOBT within one year 
were categorized as “screened, adherent” if they reported FOBT within one year and as 
“screened, not-adherent” if they reported having FOBT over a year ago. Participants age 50 
years and older were categorized as “screened, adherent” if they reported receipt of a 
colonoscopy within 10 years, receipt of a sigmoidoscopy within 5 years, or receipt of both 
within 10 years. Those who reported not being sure if they received a sigmoidoscopy or 
colonoscopy were categorized as “screened, adherent” if they received the test within 5 
years.
Prostate cancer screening—Until recently, annual PSA testing beginning at age 50 in 
men was recommended by the ACS and the USPSTF 19,23. Participants were categorized as 
“screened, adherent” if they reported receipt of the PSA test within 1 year. Those who 
reported receipt of the PSA test 2 years ago or more were categorized as “screened, non-
adherent.”
Perceived Discrimination
Perceived discrimination was measured using the Brief Perceived Ethnic Discrimination 
Questionnaire-Community Version (PEDQ). This 17-item scale has been validated in 
Hispanics/Latinos 24. The PEDQ includes four subscales of perceived discrimination: 1) 
Exclusion/rejection; 2) Stigmatization/disvaluation; 3) Discrimination at work/school; 4) 
Threat/anger. The items in each subscale begin with “Because of my ethnicity or race…” 
and end with a description of some form of mistreatment. For each of the subscales, 
participants were asked how often they “had these experiences in their lifetime.” Responses 
are on a scale from “1” (never happened) to “5” (happened very often). The items were 
added to create a summary score (possible score range 17 to 85); higher scores indicate 
greater perceived discrimination. The Cronbach’s alpha for internal consistency of the 
PEDQ was 0.87 for English and 0.91 for Spanish indicating that the instrument is valid in 
English and Spanish.
Covariates
Age, education, national background, nativity, duration of residency in the US, annual 
household income, health insurance status, health care use, and family history of cancer 
were assessed via self-report. Age group was categorized in 10-year intervals (18–29, 30–39, 
40–49, 50–59, 60–69, 70–74). Education was categorized into high school or less, high 
school equivalent, or greater than high school. The following national backgrounds were 
considered in our analysis: Dominican, Central American, Cuban, Mexican, Puerto Rican, 
South American, mixed/other). Nativity was assessed as a binary variable (US born [within 
50 US states and District of Columbia] or foreign-born [born outside 50 US states and 
District of Columbia]). Annual household income was assessed as a 3-level variable (<
$30,000; ≥$30,000; missing). Participants reporting public or private insurance were 
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categorized as insured and those that reported no insurance were categorized as uninsured. 
Family history of cancer in first-degree relatives was considered as a binary yes/no variable.
Statistical Analysis
The distribution of categorical variables was described using frequencies and weighted 
percentages. Differences in perceived discrimination by sex among persons eligible for 
cancer screening were assessed using student t-tests. Differences in colorectal cancer 
screening by sex were assessed using Pearson’s X2. Multivariable polytomous logistic 
regression models were fit to assess the association between perceived discrimination and 
cancer screening adherence. Models were adjusted for a set of potential confounders chosen 
a priori including demographic and socioeconomic behaviors that might confound the 
association of interest. We present findings from a model with relevant covariates associated 
with cancer screening including age group, nativity, field center, insurance status, and annual 
household income since further adjustments did not yield different results. Other 
confounders assessed but not included in the final model were education, national 
background, duration of residency in the US, health care use, and family history of cancer 
were assessed via self-report. All analyses accounted for the complex sampling design of 
HCHS/SOL and were conducted using SAS-callable SUDAAN 11.0 (RTI International, 
Research Triangle Park, NC).
RESULTS
Population
This analysis included 3,095 women aged 18–74 years old and 840 men aged 50–74 years 
old with complete data on cancer screening behaviors and perceived ethnic discrimination 
questionnaire (45 were excluded for missing data), and no personal history of cancer (203 
were excluded for cancer history). The SCAS sample that completed questionnaires on 
discrimination and cancer screening was similar to the overall HCHS/SOL study population 
in terms of region of residence and nativity. There were slightly higher proportions of 
Dominicans, women and higher educated people in SCAS compared to the overall 
HCHS/SOL study population (data not shown).
The distribution of sociodemographic characteristics by sex is presented in Table 1. Two 
groups of women are presented for comparison: 18–74 year olds and 40–74 year olds. The 
majority of participants were Mexican followed by Cuban, Puerto Rican, Dominican, 
Central American, and South American. Overall most respondents reported being born 
outside of the US, having resided in the US over 10 years, having a high school education or 
less, and having an annual household income of less than $30,000 (Table 1). By self-report, 
52.9% of women 18–74 years old and 40.7% of men 50–74 years old were uninsured.
Screening adherence
Table 2 reports the percentage of men and women adhering to cancer screening guidelines. 
Among women, 72.1% (95% CI: 69.2%, 74.7%) received a Pap smear within the 
recommended time frame and 71.3% (95% CI: 67.7%, 74.6%) received a mammogram 
during the recommended time frame. In participants aged 50–74, adherence to 
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recommendations for any colorectal cancer screening modality, including FOBT or 
colonoscopy or sigmoidoscopy, was not different between men and women. Adherence to 
FOBT was 24.6% (95% CI: 19.4%, 30.6%) among women and 27.0% (95% CI: 22.9%, 
31.5%) among men. Adherence to colonoscopy/sigmoidoscopy guidelines was significantly 
higher among women than among men: 43.5% (95% CI: 37.8%, 49.5%) of women and 
34.8% (95% CI: 30.0%, 39.9%) of men were adherent to colonoscopy/sigmoidoscopy 
guidelines. An estimated 41.0% (95% CI: 36.1%, 46.2%) of men were adherent to PSA 
screening guidelines.
Perceived Discrimination
Perceived discrimination scores were significantly higher among men than among women (P 
= 0.01). The mean PEDQ score was 24.0 (95% CI: 23.6, 24.4) among women and 25.4 (95% 
CI: 24.3, 26.5) among men. The results of multivariable polytomous logistic regression 
models studying the association between perceived discrimination and cancer screening 
adherence among women and men are reported in Tables 3 and 4, respectively. Among 
women, we observed no significant association of perceived discrimination with breast or 
cervical or colorectal cancer screening in unadjusted or adjusted analyses (Table 3). Among 
men, a 1-point increase in PEDQ score was associated with a 4% increase in odds of being 
screened but not adherent to FOBT guidelines compared to being screened and adherent 
(OR: 1.04, 95% CI: 1.01–1.07). However, a similar 1-point increase in PEDQ score was 
associated with a 4% decrease in odds of being screened at all for colorectal cancer via 
colonoscopy and/or sigmoidoscopy, compared to being screened and adherent (OR: 0.96, 
95% CI: 0.94, 0.99) (Table 4).
Other covariates
Nativity—US born women were significantly more likely to be screened via mammography 
outside the recommended guidelines than foreign-born women (OR: 1.82, 95% CI: 1.04–
3.21). Nativity was not consistently associated with behaviors across cancer sites. There was 
no association between nativity and cancer screening adherence for cervical cancer 
screening, prostate cancer screening, or colorectal cancer screening in both women and men.
Health insurance status—Insurance status was an important predictor of cancer 
screening for both women and men. Among women, not having health insurance was a 
significant independent predictor of not adhering to guidelines on Pap smear testing, 
mammography, and colonoscopy/sigmoidoscopy (Table 3). Among women, not having 
insurance was also statistically significantly associated with not being screened via 
mammography, FOBT, and colonoscopy/sigmoidoscopy. Among men, not having health 
insurance was a significant independent predictor of not adhering to FOBT and 
colonoscopy/sigmoidoscopy guidelines (Table 4). Not having insurance was associated with 
higher likelihood of not being screened via FOBT, colonoscopy/sigmoidoscopy, and PSA. 
Insured participants and uninsured participants had similar PEDQ scores, suggesting that 
they were equally likely to report perceived discrimination.
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DISCUSSION
Cancer is now the leading cause of death among Hispanics/Latinos in the US 1. Early 
detection of cancer through screening may reduce cancer morbidity and increase five-year 
survival rates 1. We evaluated data from a large, multicenter epidemiological study of 
Hispanics/Latinos from diverse backgrounds in four US urban areas to determine if 
perceived discrimination, defined by the PEDQ, a measure of lifetime ethnicity-related 
discrimination, was associated with lack of receiving cancer screening. In contrast to 
previous studies, we found no evidence of a significant association between perceived 
discrimination and cancer screening in women. In men, the association between 
discrimination and colorectal cancer screening reached nominal levels of statistical 
significance, albeit the direction of the association was not consistent with our hypothesis 
and the results were not consistent across screening tests.
In the Black Women’s Health Study, a convenience sample of African American women, 
higher perceived everyday discrimination was associated with reduced cervical cancer (Pap 
test) screening, but was unassociated with colorectal cancer screening 12. In the multi-ethnic 
California Health Interview 2003 and 2005 Surveys (CHIS), women who reported higher 
levels of discrimination in the medical care context (“medical discrimination”) were 
significantly less likely to be screened for both colorectal and breast cancer. This finding 
persisted after controlling for ethnicity and several health-related factors including access to 
health insurance and usual source of care. the CHIS questionnaire specifically asked about 
whether individuals perceived discrimination in medical settings, and the discordance 
between CHIS and the present study may suggest that it is important to capture 
discrimination that is perceived to occur specifically within health care settings 13. In the 
CHIS, however, no association between medical discrimination and colorectal cancer 
screening was observed in men13. Discrepancies among the findings in the Black Women’s 
Health Study, the CHIS and our study may be explained by different measurement properties 
of specific self-reported discrimination scales, or by variability among groups in the 
experience and effects of discrimination. The CHIS sample was much larger and included 
not only Hispanic/Latinos but also African American, Asian, and American Indian/
American Indians and all participants were Californians, unlike our sample which included 
U.S. residents from four different states. Other specific characteristics of the HCHS/SOL 
cohort that may be important include a predominance of Spanish speakers and immigrants 
living in large urban centers who were recruited using door-to-door recruitment methods. In 
the CHIS the respondents were selected by random digit telephone number dialing and 
included participants from rural, suburban, and urban settings. It is possible that the presence 
of extensive safety net services and community resources in the four HCHS/SOL centers, 
including government-funded screening programs, may mitigate any relationship between 
discrimination and screening behaviors that may exist elsewhere.
Several limitations of our study warrant discussion. Our definitions of cancer screening 
adherence were based on cancer screening guidelines that are subject to debate. There is 
much controversy regarding the age to begin screening and the appropriate frequency for 
each screening tests. Screening guidelines differ between major cancer organizations. 
However, we used screening guidelines from two national organizations, ACS and the 
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USPSTF to guide our definitions. During the time of study recruitment the screening 
guidelines from different organizations were more consistent with each other than they are at 
the current time.
Even with consistent guidelines in place, recommendations about cancer screening likely 
vary among primary care providers and may be dependent on individual patient 
characteristics. In the case of cervical cancer, for example, one primary care provider may 
have advised a female who initiated sexual activity during her early teenage years to initiate 
screening for cervical cancer at age 18, while another may have advised to initiate screening 
at age 21. This study did not account for the variability in provider recommendations for 
cancer screening. Indeed, evidence suggests that factors like a patient’s ethnicity, level of 
education and income may influence provider recommendations for cancer screening 24–26.
Our measure of perceived discrimination is a measure of lifetime discrimination rather than 
current, everyday, or medical discrimination. In a prior study, measures of everyday 
discrimination were strongly correlated with the global measure of perceived discrimination 
that was used here 27.
Another limitation was assessment of information about cancer screening behaviors via self-
report which is potentially subject to recall bias. It has been established that self-reported 
data may tend to overestimate the true measure of cancer screening utilization. Validation 
studies have reported that estimates of cancer screening rates are inflated in self-reported 
data, particularly among Blacks and Hispanic/Latinos 28,29. This study did not account for 
the participants’ levels of health knowledge and cancer awareness. It is possible that items in 
the HCHS/SOL cancer questionnaire used to measure cancer screening behaviors may not 
have been understood by participants with low levels of education and cancer awareness, 
leading to misclassification. Participants may have answered questionnaires in a way 
perceived as desired and/or expected, leading to false positive responses to questions about 
screening practices and underreporting of discrimination 30. Lastly, the data used in this 
study were cross-sectional. Thus, causal inferences about the associations reported in this 
study cannot be made.
Of note, screening rates for breast, cervical, colorectal, and prostate cancer in this cohort of 
Hispanic/Latinos are lower than the Healthy People 2020 goals 31. The percentages of 
screening reported in this cohort are also generally lower than studies using data from 2010 
National Health Interview Survey (NHIS) 31. Cervical cancer screening among Hispanic/
Latina women was 76.9% in NHIS and 72.1% in HCHS/SOL, both measures below the 
Healthy People 2020 target of 93.0% 32. In this study not having health insurance was a 
significant independent predictor of not receiving screening and not being up to date with 
screening. The powerful effect of health insurance status was seen for every screening test 
and among both men and women. These results are consistent with data from the 2010 
NHIS and 2010 ACS, which indicated that uninsured compared to insured persons were less 
likely to report receiving recent cancer screening. For example, uninsured women 40 and 
older were less likely to report receiving a mammogram within the past two years (31.5% 
versus 70.7%, respectively) 33.
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The HCHS/SOL SCAS cohort was mostly foreign-born and reported low levels of 
education, income and health insurance coverage. Because having insurance has been 
identified a key determinant of cancer screening, policies that increase insurance coverage 
among Hispanics/Latinos may increase screening rates in this population. The Affordable 
Care Act (ACA) has the potential to result in large reductions in uninsurance rates among 
Hispanics/Latinos 34. It remains to be seen how the implementation of the ACA will affect 
access to screening services in this vulnerable population 34, and an estimated 33.1% of 
Hispanics/Latinos may remain presently uninsured 35. Several states with large numbers of 
Hispanic/Latino residents including Texas and Florida have not taken the steps encouraged 
by the ACA to expand Medicaid to low-income adults. Additionally, more than 5 million 
undocumented people living in the US (over 80% of whom are Hispanic/Latino) will remain 
uninsured in the forseeable future 34. In this population with high levels of uninsured, 
increasing health care coverage and awareness of the existing state and sliding scale 
screening services may be important ways to increase screening. Finally, we speculate that 
in the Hispanic population, barriers relating to health insurance and related factors probably 
overwhelm or obscure any possible effects of discrimination on cancer screening adherence.
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